N-Methyl-3-azabicyclo<3.2.2>nonan | 1195-35-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环庚烷
• 英文名称: N-Methyl-3-azabicyclo<3.2.2>nonan
• 英文别名: 3-Methyl-3-aza-bicyclo<3.2.2>nonan；3-methyl-3-azabicyclo[3.2.2]nonane
• CAS: 1195-35-3
• 化学式: C₉H₁₇N
• 分子量: 139.241
• InChiKey: VYMQLQVLMDEDRO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3-氮杂双环(3.2.2)壬烷 、 alkaline earth salt of/the/ methylsulfuric acid 在 potassium hydroxide 作用下， 生成 N-Methyl-3-azabicyclo<3.2.2>nonan
  参考文献：
  名称：

  N-alkylation of N-heterocyclic ionic liquid precursors in ionic liquids

  摘要：

  室温离子液体[BMIM][PF6]和[P14][Tf2N]与 KOH 在温和条件下是仲胺 3-氮杂双环[3.2.2]壬烷烷基化反应的优良反应介质。考察的因素包括烷基卤化物链长（C1 至 C4）和卤化物特性（Cl、Br、I）。叔胺产物从反应介质中分离出来，只需简单倾析即可分离，收率很高。

  DOI：

  10.1039/b817526h

文献信息

• Organic Compounds
  申请人：Caravatti Giorgio

  公开号：US20090163469A1

  公开（公告）日：2009-06-25

  The present invention relates to compounds of formula I and its salts, wherein the substituents are as defined in the description, to compositions and use of the compounds in the treatment of diseases ameloriated by inhibition of phosphatidylinositol 3-kinase.

  本发明涉及公式I的化合物及其盐，其中取代基如描述中所定义，以及该化合物在治疗通过抑制磷脂酰肌醇3-激酶改善的疾病中的应用。
• 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE
  申请人：INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE)

  公开号：US20150099732A1

  公开（公告）日：2015-04-09

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted-2H-isoquinolin-1-one compounds that, inter alia, inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.) and/or Wnt signalling. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to inhibit Wnt signalling; to treat disorders that are ameliorated by the inhibition of PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to treat disorders that are ameliorated by the inhibition of Wnt signalling; to treat proliferative conditions such as cancer, etc.

  本发明通常涉及治疗化合物领域。更具体地，本发明涉及某些3-芳基-5-取代-2H-异喹啉-1-酮化合物，该化合物在抑制PARP（例如PARP1，TNKS1，TNKS2等）和/或Wnt信号传导方面具有作用。本发明还涉及包含这些化合物的药物组合物，以及利用这些化合物和组合物，在体内和体外，来抑制PARP（例如PARP1，TNKS1，TNKS2等）；抑制Wnt信号传导；治疗通过抑制PARP（例如PARP1，TNKS1，TNKS2等）改善的疾病；治疗通过抑制Wnt信号传导改善的疾病；治疗癌症等增生症状。
• Catalysts for polycarbonate production
  申请人：Saudi Aramco Technologies Company

  公开号：US11185853B2

  公开（公告）日：2021-11-30

  The present invention provides unimolecular metal complexes having increased activity in the copolymerization of carbon dioxide and epoxides. Also provided are methods of using such metal complexes in the synthesis of polymers. According to one aspect, the present invention provides metal complexes comprising an activating species with catalytic activity tethered to a ligand that is coordinated to the active metal center of the complex.

  本发明提供了在二氧化碳和环氧化物的共聚合中具有增强活性的单分子金属配合物。还提供了使用这种金属配合物在聚合物合成中的方法。根据一个方面，本发明提供了包含一个具有催化活性的活化物种，该活化物种被系到与复合物的活性金属中心配位的配体的金属配合物。
• Substituted Acyloxyamidines as HCV NS3/4A Inhibitors
  申请人：ViroCura Therapeutics, Inc.

  公开号：US20150133495A1

  公开（公告）日：2015-05-14

  Disclosed herein is a compound of Formula I or a pharmaceutically acceptable salt thereof, in which A, G, R 1 and R 2 are as defined herein. The compounds and pharmaceutical compositions of the compounds are suitable for the treatment of HCV infection in mammals and are also useful to modulate or inhibit NS3/4 dimerization.

  本文公开了一种I式化合物或其药学上可接受的盐，其中A、G、R1和R2的定义如本文所述。这些化合物及其制剂适用于哺乳动物HCV感染的治疗，并且也有用于调节或抑制NS3/4二聚体化的作用。
• 1,4-benzodiazepinones and their uses as CCK antagonists
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US20020183313A1

  公开（公告）日：2002-12-05

  Benzodiazepine derivatives of the formula: 1 wherein R 1 is heterocyclic(lower)alkyl which may have one or more suitable substituent(s), etc., R 2 is lower alkyl, etc., R 3 is indolyl, etc., R 4 is hydrogen, etc., or a pharmaceutically acceptable salt thereof, which are useful as a medicament.

  公式为1的苯二氮平衍生物，其中R1为杂环（较低）烷基，可以有一个或多个合适的取代基等，R2为较低的烷基等，R3为吲哚基等，R4为氢等，或其药学上可接受的盐，可用作药物。